enGene Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, enGene Therapeutics stock has a consensus rating of "Hold" and an average price target of $3.29. The average 1-year stock price forecast is 76.88% higher than the current stock price, while the lowest is $2.00 (+7.53%) and the highest is $5.00 (+168.82%).

Price Target: $3.29 (+76.88%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$2.00	$3.29	$4.00	$5.00
Change	+7.53%	+76.88%	+115.05%	+168.82%

Analyst Ratings

The average analyst rating for enGene Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	7	7	7	2	2
Buy	3	3	3	3	1	1
Hold	1	1	1	1	8	6
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	1
Total	11	11	11	11	11	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Judah Frommer Morgan Stanley	Morgan Stanley	Sell Downgrades n/a	Sell	Downgrades	n/a	n/a	Jun 18, 2026
Michael Schmidt Guggenheim	Guggenheim	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Jun 16, 2026
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Maintains $6 → $4	Buy	Maintains	$6 → $4	+115.05%	Jun 16, 2026
Yanan Zhu Wells Fargo	Wells Fargo	Hold Reiterates $2	Hold	Reiterates	$2	+7.53%	Jun 16, 2026
David Dai UBS	UBS	Hold Maintains $9 → $2	Hold	Maintains	$9 → $2	+7.53%	May 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

6.17M

EPS This Year

-1.73

from -2.29

EPS Next Year

-1.40

from -1.73

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Oct 31, 2021	Oct 31, 2022	Oct 31, 2023	Oct 31, 2024	Oct 31, 2025	Oct 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-15.87M	-19.43M	-26.06M	-62.30M	-123.17M	-119.36M
Net Income	-23.44M	-24.46M	-99.92M	-55.14M	-117.30M	-118.72M
EPS	-	-	-	-	-2.29	-1.73
Free Cash Flow	-	-10.75M	-16.07M	-32.23M	-60.38M	-140.89M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.56
Avg	-1.73
Low	-1.95

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-